Xenon Pharmaceuticals Inc
XP0
Company Profile
Business description
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Contact
200-3650 Gilmore Way
BurnabyBCV5G 4W8
CANT: +1 604 484-3300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
370
Stocks News & Analysis
stocks
ASX listed gold miner under pressure due to lower production
Shares have dropped nearly 20% since lowering 2026 volume guidance.
stocks
3 ASX opportunities after earnings season
Uncovering key opportunities following February’s results.
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
We raise our fair value estimate for Oracle stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,804.60 | 24.10 | -0.27% |
| CAC 40 | 7,935.97 | 24.44 | 0.31% |
| DAX 40 | 23,564.01 | 116.72 | 0.50% |
| Dow JONES (US) | 46,946.41 | 387.94 | 0.83% |
| FTSE 100 | 10,317.69 | 56.54 | 0.55% |
| HKSE | 26,045.84 | 211.82 | 0.82% |
| NASDAQ | 22,374.18 | 268.82 | 1.22% |
| Nikkei 225 | 53,901.23 | 150.08 | 0.28% |
| NZX 50 Index | 13,132.37 | 32.21 | -0.24% |
| S&P 500 | 6,699.38 | 67.19 | 1.01% |
| S&P/ASX 200 | 8,598.70 | 20.00 | -0.23% |
| SSE Composite Index | 4,083.03 | 1.76 | -0.04% |